Navigation Links
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
Date:7/7/2010

Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance which include Alzheimer's disease.

Madison, Wis (Vocus) July 7, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.

“Quincy Bioscience continues to strengthen its position in developing this novel calcium-binding protein as a platform technology,” said Mark Underwood, president of Quincy Bioscience. “The neuron’s ability to manage calcium and maintain homeostasis is fundamental to proper function. Research has proven the cell’s inability to regulate calcium is a key pathophysiological component in many different brain disorders, including Alzheimer’s disease. Based on our ongoing research of aequorin in various health conditions and what we know about the role of calcium in the body, we expect aequorin to be a vital protein in many aspects of healthy aging.”

Aequorin, which comes from a species of jellyfish called Aequorea victoria, is a calcium-binding protein. In humans calcium-binding proteins are utilized to maintain calcium balance which is critical to proper cell function. Aequorin has proven to be neuroprotective in pre-clinical studies performed at the University of Wisconsin-Milwaukee and has shown to be effective at improving aspects of cognition such as spatial working memory and executive function in human studies conducted by Quincy Bioscience.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4235874.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
4. Flagship Biosciences Partners with a Leading IHC CLIA Laboratory for Companion Diagnostics Service
5. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
6. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
7. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
8. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
9. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
10. Childrens Hospital Los Angeles oncologist receives $50,000 Hyundai Scholar Award
11. Stamen Medical Systems Receives Medicare Re-Accreditation and The Exemplary Provider Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... The ... and other communities across eastern Texas, is launching a cooperative charity drive with the ... families. , Serving more than 50,000 individuals and families in need, the Tarrant County ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to ... Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal implants ... the first office to be chosen by the dental implant manufacturer, Straumann, to bring ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism ... of this dance is to provide a night of fun for teens with and without ... help everyone feel welcomed and included at the event. The dance will take place on ...
(Date:2/12/2016)... Sacramento CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative ... progression of dental decay. With the recent approval by the FDA, there is a ... application similar to fluoride varnish, SDF is very simple and quick to apply. The ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology: